Mapping of Blood Group and Phenotypes Rhesus and Kell to Sickle Cell Desease Patients in Transfusion Program at the National Blood Transfusion Center (NBTC) of Abidjan Côte d’ivoire
International Journal of Immunology
Volume 3, Issue 4, August 2015, Pages: 47-51
Received: Jun. 17, 2015; Accepted: Jun. 22, 2015; Published: Jul. 4, 2015
Views 4405      Downloads 122
Authors
Sekongo Yassongui Mamadou, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire; Hematology clinic, University Hospital of Yopougon, Abidjan, Côte d’Ivoire
Kouamenan Goore Sidonie, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Kassogue Kadidia, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Konan Sidoine, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Kouassi Parfait, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Lagou Amélie Delphine, Nephrology service, University Hospital of Yopougon, Abidjan, Côte d’Ivoire
Kouacou-Ama Patricia, Immunology service, University Hospital of Cocody, Abidjan, Côte d’Ivoire
Konate Seidou, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Abisse Agba, Therapeutic and Research Unit, National Blood Transfusion Center, Abidjan, Côte d’Ivoire
Article Tools
Follow on us
Abstract
The objective of this study is to establish the mapping of blood group and phenotype Rhesus and Kell and compare it to the population of blood donors. Methodology: It is a prospective study performed in transfusion therapy unit (UTT) of the national blood transfusion center (NBTC) of Abidjan on sickle cell desease patients multitransfused between February and October 2013. The blood group ABO and phenotype Rhesus and Kell of the patients was performed by the gel agglutination technique. The statistical analysis was performed using SPSS 15.0 software. Results: Among the 145 patients followed by the UTT, males predominated with (sex ratio 1.27). The median age was 14 years. Homozygous sickle cell disease (SS) was more frequent (57.25%). The blood group O was more represented (54.6%). Ag D was found in 96%. The Ag C (16.5%) and Ag E (14.5%) have lower frequencies than those founded in the population of blood donors (Ag C 21.6% and Ag E 22.2%). The most phenotype rhesus and kell frequently encountered to the patients was C- c+ E- e+ K- (49.7%). These frequencies are lower than those of the blood donors population. Conclusion: Blood group O is the most common to our patients. The Ag D is the most found. The phenotype Rhesus and kell C- c + D + E- e- K- predominates with but remains below the frequencies reported among blood donors. This proves that there are risks of alloimmunization to these patients; hence the necessity to transfuse according to the protocol phenotyped and compatibility.
Keywords
Mapping, Blood Group and Phenotyps Rhesus and Kell, Sickle Cell Desease Patients, Transfusion Program
To cite this article
Sekongo Yassongui Mamadou, Kouamenan Goore Sidonie, Kassogue Kadidia, Konan Sidoine, Kouassi Parfait, Lagou Amélie Delphine, Kouacou-Ama Patricia, Konate Seidou, Abisse Agba, Mapping of Blood Group and Phenotypes Rhesus and Kell to Sickle Cell Desease Patients in Transfusion Program at the National Blood Transfusion Center (NBTC) of Abidjan Côte d’ivoire, International Journal of Immunology. Vol. 3, No. 4, 2015, pp. 47-51. doi: 10.11648/j.iji.20150304.11
References
[1]
Marion E. Reid et Christine Lomas-Francis, The blood group antigen, Facts Book, Elsevier Academic Press, 2° édition, 2004.
[2]
Marion E. Reid et Christine Lomas-Francis, The blood group antigen & antbodies, SBB Books New Yrok, 2007
[3]
Dembele B., Otchoumou K., Siransy B.L., Sekongo Y.M., Abissey A.S. Etude de la compatibilité érythrocytaire Rhesus Kell entre donneur de sang et receveurs à Abidjan. Rev. Int. Sc. Méd. 2009,11 ; 3 : 21-25.
[4]
Sangaré A. La douleur drépanocytaire. J Panafr Douleur 1995 : 1-12.
[5]
A.Tolo-Diebkile Drépanocytose homozygote chez l’adulte ivoirien de plus de 21 ans, John Libbey Eurotext. 2010, 20 ; 2 : 63-67
[6]
Eloundou C.O. Prise en charge de la crise douloureuse drépanocytaire selon les critères de L’OMS. Une étude en milieu hospitalier pédiatrique à Libreville. Thèse méd. Bamako : 02-M-32
[7]
Diallo D. Suivi des enfants drépanocytaires de 0-15 ans dans le service de pédiatrie du CHU GT. Thèse méd. Bamako : 04-M-16
[8]
Neonatomg Etude descriptive dans 4 centres Parisiens chez 299 patients suivi de 1987-1997. Eur J Haematol 2000
[9]
Cabannes R., Sendrail A., Pene F., Sangare A., Sombo M. E., Kple F. P. Etude de l'hémotypologie des populations d'Afrique de l'Ouest. Ann. Univ. Abidjan, 1979,13 ; B : 105-135.
[10]
Siransy Bogui L., Dembele B., Sekongo Y., Abisse S., Konaté S., and Sombo M. Phenotypic Profile of Rh and Kell Blood Group Systems among Blood Donors in Cote d’Ivoire, West Africa. Hindawi Publishing Corporation Journal of Blood Transfusion 2014, ID 309817 : 4 p
[11]
Dulat C., Rey J.L., Trolet C. Répartition ethnique des groupes sanguins en Côte d’Ivoire Méd. D’Afr. Nr. 1989, 36 (11)
[12]
Rapport d’activité du centre national de transfusion sanguine de côte d’ivoire 2010
[13]
Rapport d’activité du centre national de transfusion sanguine de côte d’ivoire 2011
[14]
Rapport d’activité du centre national de transfusion sanguine de côte d’ivoire 2012
[15]
Corrain C. Et Capitanio M.Quelques observations hémotypologiques à propos des Dida (Côte d’Ivoire) Bulletins et Mémoires de la Société d’anthropologie de Paris, 1984, 1 : 83-90
[16]
Falusi AG, Ademowo OG, Latunji CA, Okeke AC, Olatunji PO, Onyekwere TO, Jimmy EO, Raji Y, Hedi CC, Otukonyong EE, Itata EO. “Distribution of ABO and RH genes in Nigeria,” African Journal of Medicineand Medical Sciences 2000, 29 ;1 : 23–26.
[17]
Chiaroni J., Roubinet F., Bailly P., Mannessier L., Noizat-pirennef. Les analyses immunohématologiques et leurs applications cliniques, Edit : John Libbey Eurotext. 2
[18]
Daniels G., Human Blood Group, John Willey & Sons, Hoboken, NJ, USA, 2nd edition, 2002.
[19]
Wagner F.F., Kasulke D., Kerowgan M., and Flegel W.A. “Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinical relevant high-frequency antigens in southwestern Germany,” Infusions therapie und Transfusions medizin 1995, 22 ; 5 : 285–290.
[20]
Akre DP, Seka-Seka J, Dasse SR, Kple-Faget P, Hien S, N’Guessan K, Sombo MF. “Alloimmunisation anti ´erythrocytaire post transfusionnelle chez les drépanocytaires au CHU de Cocody Abidjan,” International Journal of Pharma and Bio Sciences 2008, 9 ; 2 : 64–70.
[21]
Vichensky EP, Luban N, Wright E, Olivieri N. Prospective RBC phenotype matching in a stroke-preven¬tion trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41:1086–1092.
[22]
Murao M et Viana MB. Risk factors for alloimmunization by patients with sickle- cell disease. Braz J Med Biol Res. 2005, 38 ; 5: 675-82.
[23]
Norol F, Nadjahi J, Bachir D et al. Transfusion and alloimmunization in sickle-cell anemia patients. Transfus Clin Biol.; 1994, 1 ; 1: 27-34.
[24]
Orilina AR, Ungerp J et M Koshy () Post transfusion alloimmunisation in patients with Sickle-cell anemia. Amer. J Hematol. 1978, 5 ; 1: 101-6.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186